论文部分内容阅读
长期以来,由于肿瘤宿主对肿瘤细胞不能产生有效的免疫反应,故癌症免疫治疗发展缓慢。1980年Rosenberg等首先用新方法获得大量淋巴细胞,当其与白细胞间素-2(IL-2)作用后,能溶解新鲜、未曾培养的原发或转移癌细胞。这种淋巴因子活化杀伤细胞(LAK细胞)由于能溶解对自然杀伤细胞(NK细胞)耐受的肿瘤细胞,故在功能上有别于NK细胞。此外LAK细胞对肿瘤细胞具有特异性,对正常细胞几乎无影响。对非免疫基因、同种基因及同系
For a long time, cancer immunotherapy has developed slowly due to the tumor host’s failure to produce an effective immune response against tumor cells. In 1980, Rosenberg et al. first used new methods to obtain a large number of lymphocytes that, when they interact with interleukin-2 (IL-2), can dissolve fresh, uncultured primary or metastatic cancer cells. This lymphokine activated killer cell (LAK cell) is functionally distinct from NK cells because it can dissolve tumor cells that are resistant to natural killer cells (NK cells). In addition, LAK cells are specific to tumor cells and have little effect on normal cells. For non-immune genes, homologous genes and homologs